Compare Cytokinetics Inc (CYTK) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs General Motors Company — how do they compare? Cytokinetics Inc trades at $76.58 (market cap $10.63B), while General Motors Company trades at $87.06 (market cap $78.40B). The key difference: General Motors Company is far larger — about 7.4× Cytokinetics Inc's market cap, and General Motors Company pays a 0.81% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | GM | |
|---|---|---|
Market Cap | $10.63B | $78.40B |
Sector | Technology | Consumer Cyclical |
52-Week High | $87.26 | $90.30 |
52-Week Low | $34.31 | $54.16 |
Enterprise Value | $10.74B | $181.38B |
Dividend Yield | — | 0.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
General Motors (GM) trades at $87.96, up 0.43% with a bullish technical signal and strong analyst support. The company shows robust cash flow generation ($26.87B operating cash flow in 2025) and has beaten earnings estimates for three consecutive quarters. Recent developments include a $4.5B parts supply deal and a renewed 20-year joint venture in China, positioning GM for supply chain stability and international growth.
GM presents a compelling investment case with 65% analyst buy ratings and a $108.82 consensus price target offering 24% upside. However, declining profit margins (1.05% net margin in 2025) and rising debt levels (46.79% debt-to-asset ratio) warrant caution. The stock's valuation appears reasonable with P/S of 0.45 and P/B of 1.26, but investors should monitor execution on EV strategy transitions and macroeconomic pressures on auto demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
